All In Biotech

NDA 021150 · Kenvue Brands

Zyrtec-D 12 Hour

Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Aug 10, 2001

Approved uses

3

Original approval plus efficacy supplements

Registered trials

134

35 Phase 3, 7 recruiting

FAERS reports

3,003

1,129 serious, 320 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 6, 2026.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat nasal congestion reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYRTEC-D 12 HOUR · CETIRIZINE HYDROCHLORIDE 5MG; PSEUDOEPHEDRINE HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Cetirizine" as an intervention, any sponsor and status, largest first.

All 134 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective563
  • fatigue414
  • pain407
  • off label use389
  • rash361
  • abdominal discomfort339
  • alopecia335
  • rheumatoid arthritis331
  • pemphigus330
  • systemic lupus erythematosus320
  • product use issue306
  • maternal exposure during pregnancy304

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
200613
200735
20084
20103
20114
201227
201355
201448
2015293
2016348
2017289
2018140
2019157
2020189
2021175
2022227
2023271
2024258
2025300
2026165

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 531 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.